Currently, there are 47.82M common shares owned by the public and among those 41.36M shares have been available to trade.
The company’s stock has a 5-day price change of 104.28% and -32.15% over the past three months. CABA shares are trading -83.17% year to date (YTD), with the 12-month market performance down to -72.48% lower. It has a 12-month low price of $1.76 and touched a high of $26.35 over the same period. CABA has an average intraday trading volume of 1.64 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 12.24%, -2.45%, and -60.40% respectively.
Institutional ownership of Cabaletta Bio Inc (NASDAQ: CABA) shares accounts for 89.53% of the company’s 47.82M shares outstanding.
It has a market capitalization of $236.95M and a beta (3y monthly) value of 2.32. The earnings-per-share (ttm) stands at -$2.16. Price movements for the stock have been influenced by the stock’s volatility, which stands at 23.04% over the week and 15.37% over the month.
Earnings per share for the fiscal year are expected to decrease by -40.16%, and -13.13% over the next financial year.
Looking at the support for the CABA, a number of firms have released research notes about the stock. UBS stated their Buy rating for the stock in a research note on October 10, 2024, with the firm’s price target at $10. Jefferies coverage for the Cabaletta Bio Inc (CABA) stock in a research note released on February 05, 2024 offered a Buy rating with a price target of $36. William Blair was of a view on November 29, 2023 that the stock is Outperform, while Cantor Fitzgerald gave the stock Overweight rating on October 24, 2023, issuing a price target of $40. Stifel on their part issued Buy rating on October 19, 2023.
